美国微创青光眼手术有效性:IRIS注册研究2013-2019
该多中心回顾性队列研究基于IRIS注册数据,纳入2013至2019年接受Xen凝胶支架植入、内窥镜睫状体光凝或房角切开/小梁切开术的79363只眼,评估联合或不联合超声乳化白内障吸除的微创青光眼手术有效性。结果显示联合超声乳化者再手术率更低,尤其ECP和房角切开/小梁切开术;单纯MIGS术后2年累积再手术率ECP为15%、Xen为24%、房角切开/小梁切开为24%。
要点
- 联合超声乳化白内障吸除的MIGS再手术率低于单纯MIGS,ECP和房角切开/小梁切开术差异最明显。
- 单纯MIGS术后2年累积再手术率:ECP 15%、Xen 24%、房角切开/小梁切开24%,联合超声乳化分别为3%、19%、6%。
- 黑人种族、高龄、中重度青光眼、较高基线眼压及青光眼亚型与再手术风险升高相关;MIGS并发症率低(ECP 1%、Xen 1%、房角切开/小梁切开2%)。
核心结论
- 在美国当前临床实践中,MIGS联合超声乳化白内障吸除的再手术率显著低于单纯MIGS,尤其ECP和房角切开/小梁切开术。
- 约六分之一接受单纯ECP的患者和四分之一接受单纯Xen植入或房角切开/小梁切开的患者在2年内需要再手术。
- 黑人种族、中重度青光眼诊断编码和较高基线眼压与MIGS术后再手术风险升高相关。
研究设计与样本
- 多中心回顾性队列研究,基于IRIS注册数据,纳入2013至2019年接受Xen凝胶支架(内路)植入、内窥镜睫状体光凝或房角切开/小梁切开的患者。
- 共纳入57561例患者的79363只眼,其中15118只眼(19%)接受单纯MIGS,64245只眼(81%)接受MIGS联合超声乳化白内障吸除。
- 采用Kaplan-Meier生存分析评估再手术率,再手术定义为初始手术后1个月至3年内发生的任何后续青光眼手术;采用多变量Cox比例风险模型确定再手术预测因素。
主要发现
- 联合超声乳化白内障吸除的患者再手术率低于单纯MIGS,ECP和房角切开/小梁切开术差异最明显。
- 术后第2年累积再手术率:单纯ECP 15%、单纯Xen植入24%、单纯房角切开/小梁切开24%,联合超声乳化分别为ECP 3%、Xen植入19%、房角切开/小梁切开6%(每种单纯MIGS与联合超声乳化比较P < 0.001)。
- 黑人种族、高龄、中度和重度青光眼、较高基线眼压及青光眼亚型与再手术风险升高相关。
- 所有组眼压均下降,单纯MIGS平均眼压下降更明显。
- MIGS并发症率总体较低:ECP 1%、Xen植入1%、房角切开/小梁切开2%。
关键数值与推荐
- 再手术定义为初始手术后1个月至3年内发生的任何后续青光眼手术。
- 单纯MIGS术后2年累积再手术率:ECP 15%、Xen植入24%、房角切开/小梁切开24%。
- 联合超声乳化白内障吸除的MIGS术后2年累积再手术率:ECP 3%、Xen植入19%、房角切开/小梁切开6%。
- 每种单纯MIGS与联合超声乳化比较再手术率差异P < 0.001。
- MIGS并发症率:ECP 1%、Xen植入1%、房角切开/小梁切开2%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the effectiveness of microinvasive glaucoma surgery (MIGS) with and without concurrent phacoemulsification. DESIGN: Multicenter, retrospective cohort study. PARTICIPANTS: Patients in the Intelligent Research in Sight (IRIS®) Registry who underwent Xen gel stent (ab interno) implantation, endoscopic cyclophotocoagulation (ECP), or goniotomy or canaloplasty from 2013 through 2019. METHODS: Kaplan-Meier survival analysis was used to assess reoperation rates. We defined reoperation as any subsequent glaucoma surgery occurring 1 month to 3 years after the initial procedure. Multivariable Cox proportional hazard models were used to determine factors predictive of reoperation. MAIN OUTCOME MEASURES: Reoperation rate, mean intraocular pressure (IOP) and visual acuity (VA), postoperative complications, predictors of reoperation, and reoperation procedure type. RESULTS: A total of 79 363 eyes from 57 561 patients were included, with 15 118 eyes (19%) receiving stand-alone MIGS and 64 245 eyes (81%) receiving MIGS concurrent with phacoemulsification. Overall, patients who underwent MIGS concurrently with phacoemulsification showed lower reoperation rates compared with stand-alone MIGS, most pronounced in ECP and goniotomy or canaloplasty. At postoperative year 2, the cumulative reoperation rate for stand-alone procedures was 15% for ECP, 24% for Xen implantation, and 24% for goniotomy or canaloplasty compared with 3% for ECP, 19% for Xen implantation, and 6% for goniotomy or canaloplasty concurrent with phacoemulsification (P < 0.001 for each stand-alone MIGS vs. MIGS with phacoemulsification). Black race, older age, moderate and severe glaucoma, higher baseline IOP, and glaucoma subtype were associated with higher reoperation risk. Although IOP decreased in all groups, stand-alone MIGS showed a more substantial decrease in mean IOP. Complication rates from MIGS were low overall: 1% for ECP, 1% for Xen implantation, and 2% for goniotomy or canaloplasty. CONCLUSIONS: In current United States clinical practice, MIGS has substantially lower reoperation rates when performed with phacoemulsification, especially for ECP and goniotomy or canaloplasty. Approximately one-sixth of patients undergoing stand-alone ECP and one-quarter of patients undergoing stand-alone Xen implantation or goniotomy or canaloplasty require reoperation by 2 years. Black race, diagnosis coding of moderate to severe glaucoma, and higher baseline IOP were associated with higher risk of reoperation after MIGS procedures. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
引用
- Yang SA, Ciociola EC, Mitchell W, et al. Effectiveness of Microinvasive Glaucoma Surgery in the United States: Intelligent Research in Sight Registry Analysis 2013-2019. Ophthalmology. 2022. PMID: 36522820. doi:10.1016/j.ophtha.2022.10.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。